Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1/2a study of HDP-101 in relapsed or refractory multiple myeloma
2024-515273-10-00Phase 2Authorised
- Sponsor
- Heidelberg Pharma AG
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cyclic Peptides → Modified Peptides → Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of HDP-101 in multiple myeloma (MM), sponsored by Heidelberg Pharma AG. Primary endpoints: Dose-limiting toxicity and Objective response rate. Planned start Oct 2021; status: authorised.
02
Drugs
HDP-101
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-515273-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515273-10-00.